More than 150 people took part as Providence Cancer Center participated in Vice President Biden’s Cancer Moonshot Summit. The goal is to make a decade worth of advances toward a cure in five years, from increasing access to treatment and improving care to freeing trapped data and unleashing new breakthroughs.
Excited by the promise and power of immunotherapy research, Providence Cancer Center supporters raised nearly $1 million in the month of May, with most of that coming at the 2016 Creating Hope through Innovation Dinner May 25.
Providence Cancer Center is currently enrolling patients in more than 20 studies investigating a broad spectrum of breast cancer therapies and interventions.
Amber Watters, DDS, a dental oncologist with Providence Oral, Head and Neck Cancer Program and Clinic, has opened a clinical study of a device that could lessen the effects of trismus, even in patients years or decades out from their diagnosis and treatment.
More than 30 phase I clinical trials are currently open at Providence Cancer Center.
Just a year into her career as a Providence Cancer Center radiation oncologist and scientist, Kristina Young, M.D., Ph.D., has been recognized as...
Long-time Providence Cancer Center oncology social worker Krista Nelson has been selected to join the Board of Trustees for the Association of Community Cancer Centers, or ACCC. She joins leading cancer clinicians and experts from across the country in serving on the board.
Research led by Providence Health & Services has found Medicaid coverage results in significantly higher rates of several common cancer screenings, especially among women. Cancer screenings are often the best way to catch cancer early, resulting in better outcomes and survival rates.
Providence researchers have identified an immunotherapy approach that synergizes with radiation so well it not only eliminated the tumor in most preclinical models with pancreatic cancer, it found and destroyed distant, cancer cells – which could have grown into lethal metastatic tumors.
Providence Cancer Center researchers might have identified how to determine if a patient with advanced melanoma will likely respond to a certain immunotherapy treatment.